Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion
CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced it will deliver eight presentations showcasing its mRNA cell engineering platform at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 16-20, 2023 at the Los Angeles Convention Center.
Susan McClatchey, Vice President, Quality at Eterna Therapeutics, will participate in a fireside chat, hosted by Citeline, about the manufacturing of gene therapies.
Title: Overcoming the Manufacturing and Regulatory Challenges for Gene Therapies
Date/Time: May 17, Doors open 6:00 PM PT
Speaker: Susan McClatchey, Vice President, Quality at Eterna Therapeutics
Location: Grammy Museum, 800 W Olympic Blvd, Los Angeles, CA 90015
Details of Eterna’s poster presentations are below, including several posters presented by or in conjunction with Eterna’s discovery partner, Factor Bioscience.
Title: Rational Design of Multivalent Ionizable Lipid Delivery Systems for mRNA Delivery to Blood Cells
Abstract & Poster Board Number: 563
Presenter: Elizabeth Belcher, Research Associate I at Eterna Therapeutics
Session & Location: Wednesday Poster Session, West Hall A
Date/Time: May 17, 12:00-2:00 PM PT
Title: A Scalable, iPS Cell Derived Lymphocyte and Myeloid Multi-Cell-Type Therapeutic Platform for Enhanced Tumor Cell Killing*
Abstract & Poster Board Number: 616
Presenter: Abigail J. Blatchford, Associate Scientist at Factor Bioscience
Session & Location: Wednesday Poster Session, West Hall A
Date/Time: May 17, 12:00-2:00 PM PT
Title: Chemically Modified Single-Stranded DNA Donors Enable Efficient mRNA Gene Editing-Mediated Knock-In in Human iPS Cells*
Abstract & Poster Board Number: 1065
Presenter: Claire Aibel, Associate Scientist at Factor Bioscience
Session & Location: Thursday Poster Session, West Hall A
Date/Time: May 18, 12:00-2:00 PM PT
Title: Efficient Transgene Knock-In in Human iPS Cells Combined with Small Molecule-Mediated “On-Switch” Yields Clonal Populations of Engineered Tissue-Specific Cells*
Abstract & Poster Board Number: 1103
Presenter: Taeyun Kim, Associate Scientist at Factor Bioscience
Session & Location: Thursday Poster Session, West Hall A
Date/Time: May 18, 12:00-2:00 PM PT
Title: Novel Ionizable Lipids Derived from 2-Hydroxypropylamine and Spermine for mRNA-LNP Delivery*
Abstract & Poster Board Number: 1262
Presenter: Ariadna Lubinus, Associate Scientist at Factor Bioscience
Session & Location: Friday Poster Session, West Hall A
Date/Time: May 19, 12:00-2:00 PM PT
Title: Directed Differentiation of Gene Edited iPSCs by Small-Molecule Inhibition of a Transgene-Encoded Protein
Abstract & Poster Board Number: 1314
Presenter: Raven Dance Klee, Research Associate II at Eterna Therapeutics
Session & Location: Friday Poster Session, West Hall A
Date/Time: May 19, 12:00-2:00 PM PT
Title: Gene Editing Proteins with Nickase Functionality Enable Scarless Targeted Gene Insertion in Primary Human Cells
Abstract & Poster Board Number: 1516
Presenter: Elizabeth Belcher, Research Associate I at Eterna Therapeutics
Session & Location: Friday Poster Session, West Hall A
Date/Time: May 19, 12:00-2:00 PM PT
Title: mRNA Cell Engineering Enables Rapid Prototyping of Macrophage Gene-Editing Strategies for Cancer Immunotherapy Applications*
Abstract & Poster Board Number: 1563
Presenter: Ian Hay, Associate Scientist at Factor Bioscience
Session & Location: Friday Poster Session, West Hall A
Date/Time: May 19, 12:00-2:00 PM PT
Abstracts are available on the ASGCT Annual Meeting website here.
*Research conducted and presented by discovery partner Factor Bioscience.
About Eterna Therapeutics Inc.
Eterna Therapeutics is a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines. Eterna has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing proteins, and the ToRNAdo™ mRNA delivery system from Factor Bioscience. NoveSlice™, UltraSlice™, and ToRNAdo™ are trademarks of Factor Bioscience. For more information, please visit www.eternatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that are not statements of historical fact and may be identified by terminology such as “believe,” “could,” “estimate,” “anticipate,” “expect,” “plan,” “possible,” “potential,” “project,” “will” or other similar words and the negatives of such words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those stated or implied in any forward-looking statement as a result of various factors, including, but not limited to, uncertainties related to: (i) the evolution of Eterna’s business model into a platform company focused on mRNA, iPS cell and gene editing technologies; (ii) Eterna’s ability to successfully, cost-effectively and efficiently develop its technology and products; (iii) Eterna’s ability to successfully commence clinical trials of any products on a timely basis or at all; (iv) Eterna’s ability to successfully fund and manage the growth of its development activities; and (v) Eterna ’s ability to obtain regulatory approvals of its products for commercialization. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this communication speak only as of the date on which they were made, and Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law. Factors that may cause Eterna’s actual results to differ from those expressed or implied in forward-looking statements contained in this press release are more fully disclosed in Eterna’s periodic public filings with the U.S. Securities and Exchange Commission, particularly under the heading “Risk Factors” in Eterna’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as under similar headings in Eterna’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
Investor Relations Contact:
investors@eternatx.com
Media Contact:
EternaPR@westwicke.com
